MinichMacGregor Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

MinichMacGregor Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-524	Closed	-$431K	–	104
2023 Q1	$431K	Buy	524 +450	+608%	+$339K	0.14%	62
2022 Q4	$53.4K	Buy	+74	New	+$54.6K	0.02%	173
2018 Q4	–	Sell	-47	Closed	-$18K	–	413
2018 Q3	$18K	Sell	47 -21	-31%	-$7.99K	0.01%	230
2018 Q2	$23K	Sell	68 -74	-52%	-$23.1K	0.02%	196
2018 Q1	$48K	Sell	142 -2	-1%	-$696	0.04%	116
2017 Q4	$54K	Buy	144 +7	+5%	+$2.83K	0.04%	107
2017 Q3	$61K	Buy	137 +71	+108%	+$33.8K	0.05%	93
2017 Q2	$32K	Sell	66 -63	-49%	-$27.6K	0.03%	133
2017 Q1	$49K	Sell	129 -2	-2%	-$741	0.04%	103
2016 Q4	$48K	Sell	131 -35	-21%	-$13.3K	0.04%	110
2016 Q3	$66K	Sell	166 -1	-0.6%	-$401	0.06%	91
2016 Q2	$58K	Hold	167	–	–	0.05%	97
2016 Q1	$60K	Buy	+167	New	+$68.8K	0.06%	92

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MinichMacGregor Wealth Management's REGN Position: Q2 2023 in Review

MinichMacGregor Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 524 shares — an estimated $431K sold.

MinichMacGregor Wealth Management first reported a position in REGN in Q1 2016 and held it in 13 quarters. The position peaked at $431K in Q1 2023. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

MinichMacGregor Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
MinichMacGregor Wealth Management sold 524 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $431K.
MinichMacGregor Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 13 quarters.
MinichMacGregor Wealth Management's Regeneron Pharmaceuticals position peaked at $431K in Q1 2023.
1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on MinichMacGregor Wealth Management's 13F filing for Q2 2023, filed 13 Jul 2023.